Stroke and thromboembolism in atrial fibrillation.

We performed a systematic review of the available evidence on the relationship between the individual clinical, echocardiographic and laboratory characteristics of patients with atrial fibrillation (AF) and the risk of stroke. A systematic review was also performed of all published stroke risk stratification models, as well as the accuracy of their discriminative ability between risk strata. Third, we reviewed the literature on cost-effectiveness analyses with oral anticoagulation in AF. From the systematic review on stroke risk factors, a prior stroke or transient ischemic attack (15/16 studies positive, risk ratio [RR] 2.86), hypertension (11/20 studies positive, RR 2.27), aging (9/13 studies positive, RR 1.46 per decade increase), structural heart disease (9/13 studies positive, RR 2.0) and diabetes (9/14 studies positive, RR 1.62) were found to be good independent predictors of stroke. Supportive evidence was found for sex (8/22 studies positive, RR 1.67), vascular disease (6/17 studies positive, RR 2.61) and heart failure (7/18 studies positive, RR 1.85). The various risk stratification schemes classified variable proportions as low, moderate and high risk, but the CHA(2)DS(2)-VASc score classified the smallest proportion of patients as 'low risk'. Anticoagulation with vitamin K antagonists and dabigatran is cost-effective in patients at high risk of stroke, but not in patients without any other stroke risk factor beside AF. Continued efforts are warranted to improve the antithrombotic management of AF patients to identify, and challenge, risk factors and refine risk stratification models in order to realize an individualized tailored, risk factor-based approach.

[1]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[2]  A. Mcguire,et al.  Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. , 1998, Stroke.

[3]  G. Lip,et al.  Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study , 2012, BMJ : British Medical Journal.

[4]  G. Lowe,et al.  ABC of Atrial Fibrillation: ANTITHROMBOTIC TREATMENT FOR ATRIAL FIBRILLATION , 1996, BMJ.

[5]  S. Pauker,et al.  Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. , 1998, Chest.

[6]  A. Hofman,et al.  A longitudinal population‐based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999 , 2006, Journal of thrombosis and haemostasis : JTH.

[7]  B. Gage,et al.  Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.

[8]  J. Kluger,et al.  Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin , 2012, Circulation. Cardiovascular quality and outcomes.

[9]  M. Overgaard,et al.  Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark , 2012, Journal of medical economics.

[10]  A. Tjønneland,et al.  Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study , 2011, Journal of thrombosis and haemostasis : JTH.

[11]  J. Kluger,et al.  Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. , 2012, The American journal of cardiology.

[12]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[13]  R. Cheung Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. , 1998, JAMA.

[14]  William C. Cockerham Physicians , 2001, BMJ : British Medical Journal.

[15]  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.

[16]  A R Feinstein,et al.  Risk for systemic embolization of atrial fibrillation without mitral stenosis. , 1990, The American journal of cardiology.

[17]  Steven J Edwards,et al.  Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. , 2006, Thrombosis research.

[18]  D. Singer,et al.  Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[19]  R. de Caterina,et al.  Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) , 2008, Stroke.

[20]  M. Prins,et al.  Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study , 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[21]  G. Lip,et al.  Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial , 2011, BMJ : British Medical Journal.

[22]  A. Waldo,et al.  Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme , 2009 .

[23]  L. Frost,et al.  Age and Risk of Stroke in Atrial Fibrillation: Evidence for Guidelines? , 2007, Neuroepidemiology.

[24]  D. Singer,et al.  Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.

[25]  L. Pearce Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. , 1995, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[26]  W. Aronow,et al.  Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. , 1989, The American journal of cardiology.

[27]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[28]  D. Singer,et al.  Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.

[29]  Gregory Y H Lip,et al.  Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.

[30]  M. Rosenqvist,et al.  Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.

[31]  A. Algra,et al.  Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. , 1995, Stroke.

[32]  G. Breithardt,et al.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[33]  Paul Robinson,et al.  Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation , 2012, Heart.

[34]  V. Fuster,et al.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation , 2001 .

[35]  L. Køber,et al.  Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. , 2012, The American journal of medicine.

[36]  U. Ikeda,et al.  Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1998, American heart journal.

[37]  D. Lane,et al.  A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.

[38]  Daniel Levy,et al.  Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .

[39]  G. Lip,et al.  Reliable Identification of “Truly Low” Thromboembolic Risk in Patients Initially Diagnosed With “Lone” Atrial Fibrillation: The Belgrade Atrial Fibrillation Study , 2012, Circulation. Arrhythmia and electrophysiology.

[40]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[41]  J. Halperin,et al.  Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. , 2000, The American journal of medicine.

[42]  B. Norrving,et al.  Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. , 1992, BMJ.

[43]  G. Samsa,et al.  Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation , 2011, Stroke.

[44]  G. Lip,et al.  Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. , 2007, QJM : monthly journal of the Association of Physicians.

[45]  J. Senges,et al.  Risk of thromboembolic events in patients with atrial flutter. , 1998, The American journal of cardiology.

[46]  Samuel Wann,et al.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.

[47]  A. Hofman,et al.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.

[48]  Donald R. Lynch Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[49]  Yuchiao Chang,et al.  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.

[50]  Gregory Y H Lip,et al.  Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.

[51]  D K Owens,et al.  Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.

[52]  Leon Poller,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[53]  W. Aronow,et al.  Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. , 1998, The American journal of cardiology.

[54]  S. Connolly,et al.  Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective , 2011, Thrombosis and Haemostasis.

[55]  Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .

[56]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[57]  R. Thomson,et al.  Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation , 2000, The Lancet.

[58]  D. Singer,et al.  Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.

[59]  N. Desbiens Deciding on Anticoagulating the Oldest Old with Atrial Fibrillation: Insights from Cost‐Effectiveness Analysis , 2002, Journal of the American Geriatrics Society.

[60]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[61]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[62]  A. Banerjee,et al.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.

[63]  J. Kastrup,et al.  Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. , 1990 .

[64]  G. Lip,et al.  Atrial fibrillation and upper limb thromboembolectomy: a national cohort study , 2011, Journal of thrombosis and haemostasis : JTH.

[65]  Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003 .

[66]  R. Hart Stroke prevention in atrial fibrillation , 2000, Current cardiology reports.

[67]  E. Rahme,et al.  Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. , 2012, JAMA.

[68]  A. Laupacis,et al.  A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. , 2003, Archives of internal medicine.

[69]  G. Lip,et al.  Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. , 2012 .

[70]  J. Finsterer,et al.  Mortality and rate of stroke or embolism in atrial fibrillation during long‐term follow‐up in the embolism in left atrial thrombi (ELAT) study , 2004, Clinical cardiology.

[71]  D. Singer,et al.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.

[72]  D. Levy,et al.  Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.

[73]  M. Wallander,et al.  Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. , 2009, International journal of cardiology.

[74]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[75]  M. Brainin,et al.  Transesophageal Echocardiography To Assess Embolic Risk in Patients with Atrial Fibrillation , 1998, Annals of Internal Medicine.

[76]  H. Inoue,et al.  Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. , 2000, The American journal of cardiology.

[77]  J. Plumb,et al.  Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.

[78]  Samuel Wann,et al.  [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.

[79]  D. Singer,et al.  Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.

[80]  R. P. Zhu,et al.  Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.

[81]  Lian-Yu Lin,et al.  Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. , 2011, Atherosclerosis.

[82]  D. Singer,et al.  Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. , 2009, American heart journal.

[83]  R McBride,et al.  Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.

[84]  B. Gage,et al.  Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.

[85]  Munir Pirmohamed,et al.  Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.

[86]  G. Lip,et al.  Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2012, Chest.

[87]  G. Guyatt,et al.  The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. , 2001, Chest.

[88]  J. Halperin,et al.  Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.

[89]  J. Tolstrup,et al.  Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.

[90]  Stirling Bryan,et al.  Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation , 2011, Stroke.

[91]  Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. , 1998, Archives of internal medicine.

[92]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[93]  L. Fauchier,et al.  Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 , 2010, Thrombosis and Haemostasis.